Apnimed, Inc. will present five abstracts at the CHEST 2026 Annual Meeting, including late-breaking data from Phase 3 trials of its investigational drug AD109 for obstructive sleep apnea (OSA). The presentations include rapid-fire oral and poster sessions highlighting AD109's potential to improve oxygenation and address the neuromuscular causes of OSA. Additionally, real-world studies on OSA's impact on quality of life and symptom agreement between patients and physicians will be shared. Apnimed's NDA for AD109 is under FDA review with a target decision date of February 28, 2027, marking a potential new oral treatment option for OSA.
Apnimed's presentation of abstracts at CHEST 2026 offers context for readers interested in healthcare developments. As of Oct 13, 2026 03:02 WIB, 66 of 128 priced Health-sector US stocks on Pluang rose while 61 fell. Notable movers include TLRY at USD 3.35 with a 1-day change of -5.23%, TWST at USD 151.54 down 5.16%, and WGS at USD 63.86 down 5.15%.
Pepeto, a new Ethereum-based cryptocurrency, has launched its page on CoinMarketCap, indicating a Binance listing is near. The project features a working bridge across Ethereum, BNB Chain, and Solana, with zero-cost token transfers and AI contract ch...
Crédit Agricole has signed an agreement to acquire 100% of IKB Deutsche Industriebank, a key financier for Germany's Mittelstand companies. This acquisition strengthens Crédit Agricole's expansion in Germany, Europe's largest economy, aligning with i...
Crédit Agricole has signed an agreement to acquire 100% of IKB Deutsche Industriebank, a key financial partner for Germany's Mittelstand companies. This acquisition aligns with Crédit Agricole's ACT 2028 strategic plan to expand in Europe, particular...
The complicated urinary tract infections (cUTI) market is projected to expand steadily through 2036, driven by increasing antimicrobial resistance, higher rates of recurrent and hospital-acquired infections, and more patients with underlying conditio...
Integrated Power Services (IPS) has acquired Bold Renewables, the exclusive OEM provider of parts and field services for Advanced Energy solar inverters. This acquisition strengthens IPS's renewable energy platform by adding specialized inverter life...
